Canadian optical molecular imaging developer ART Advanced Research Technologies launched a new line of biomarker products, called Fenestra, at the American Association for Cancer Research (AACR) meeting in Washington, DC, this week.
The first products in the family are Fenestra VC and Fenestra LC, designed for use in microCT imaging applications to provide researchers studying various disease models, including cancer, with vascular and hepatobiliary imaging enhancement. The agents could also be adapted for PET/CT studies of small animals, the Saint-Laurent, Quebec-based company said.
ART acquired the Fenestra technology from its purchase of Alerion Biomedical earlier this year. The agents are comprised of iodinated lipids that provide contrast enhancement, integrated into an oil-in-water lipid emulsion that selectively localizes the lipids to various sites within the body.
By AuntMinnie.com staff writers
March 31, 2006
Related Reading
ART begins Princess Margaret trial, March 22, 2006
ART posts sales gains in Q4, but loss widens, March 10, 2006
ART to buy Alerion, February 15, 2006
ART begins SoftScan study in western Canada, November 24, 2005
ART sales increase in Q3, November 3, 2005
Copyright © 2006 AuntMinnie.com
